ArticleNeuro-oncology2016
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.Cancer immunology, immunotherapy : CII · 2019Trial
- Octacosanol Suppresses Lung Cancer Metastasis and Angiogenesis via Targeting MMPs and VEGF.Cells · 2026Article
- In Silico Approach to Model Heat Distribution of Magnetic Hyperthermia in the Tumoral and Healthy Vascular Network Using Tumor-on-a-Chip to Evaluate Effective Therapy.Pharmaceutics · 2024Article
- Article
- The role of angiogenic growth factors in the immune microenvironment of glioma.Frontiers in oncology · 2023Review
- DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.Clinical neuroradiology · 2021Article
- Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.Journal of molecular histology · 2021Article
- Disabling VEGF-Response of Purkinje Cells by Downregulation ofInternational journal of molecular sciences · 2021Article
- A novel lncRNA, RPL34-AS1, promotes proliferation and angiogenesis in glioma by regulating VEGFA.Journal of Cancer · 2021Article
- LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma.Frontiers in oncology · 2021Article
- Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.Frontiers in oncology · 2021Review
- Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.Molecular oncology · 2020Article
- Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.International journal of molecular sciences · 2020Review
- Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.Clinical epigenetics · 2019Article
- Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.Brain pathology (Zurich, Switzerland) · 2019Article
- Neuropilins in the Context of Tumor Vasculature.International journal of molecular sciences · 2019Review
- Dual integrin αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance Imaging.Nanoscale research letters · 2018Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Peter BaumgartenInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Anna-Eva BlankInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Kea FranzInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Elke HattingenInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Maika DunstInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Pia ZeinerInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Katharina HoffmannInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Oliver BährInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Lisa MäderInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Benjamin GoeppertInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Marcia MacheinInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Volker SeifertInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Joachim P SteinbachInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Karl H PlateInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Patrick N HarterInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
Michel MittelbronnInstitute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany (P.B., A.-E.B., M.D., P.Z., K.H., L.M., K.H.P., P.N.H., M.Mi.); Department of Neurosurgery, Goethe University, Frankfurt, Germany (K.F., V.S.); Dr. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany (K.F., O.B., J.P.S.); Department of Neuroradiology, University of Frankfurt am Main, Frankfurt am Main, Germany (E.H.); Department of Neurosurgery, University Hospital, Freiburg, Germany (M.Ma.); Cancer Consortium (DKTK), Heidelberg, Germany (O.B., J.P.S., K.H.P, P.N.H., M.Mi.); German Cancer Research Center (DKFZ), Heidelberg, Germany (O.B., J.P.S., K.H.P., P.N.H., M.Mi.); Department of Pathology, University of Heidelberg, Heidelberg, Germany (B.G.).
German Cancer Research Center · DEGoethe University Frankfurt · DEHeidelberg University · DEUniversity Medical Center Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA major hallmark of malignant progression in human astrocytomas is the formation of new blood vessels. Antiangiogenic therapy using the anti-vascular endothelial growth factor (VEGF)-antibody bevacizumab leads to increased progression-free survival in glioblastoma patients but does not influence their overall survival. To date, it is unclear why antiangiogenic therapy fails in many glioblastoma patients, while a small subpopulation profits considerably from this treatment.
methodsThe aim of our study was to determine the expression of VEGF-A and its (co-) receptors by immunohistochemistry and to test the association with patient survival in 350 glioma patients. Additionally, VEGF-A expression was analyzed by in-situ hybridization. In 18 patients, the protein expression was compared with the bevacizumab response according to extended and modified RANO criteria.
resultsWe found a heterogeneous expression pattern of VEGF and its receptors in glioblastoma patients with significantly lower levels in WHO grade II and III tumors and normal-appearing brain tissue (P < .001). Pilocytic astrocytomas (WHO grade I) showed significantly higher VEGFR-1, -2 and neuropilin-1 levels as compared to WHO grade II and III astrocytomas (P < .01) but at lower levels than glioblastomas. The expression of neuropilin-2 was low in all tumors. There was neither a significant correlation between protein expression and patient survival nor between protein levels and bevacizumab response after modified RANO criteria.
conclusionSince our data indicate that beneficial response to bevacizumab treatment is independent of the expression of VEGF-A and its (co-) receptors, further investigation is needed to decipher the underlying mechanisms of antiangiogenic treatment response.
Indexed as
AdolescentAdultAgedAged, 80 and overAngiogenesis InhibitorsAstrocytomaBevacizumabBiomarkers, TumorBrain NeoplasmsChildChild, PreschoolFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesInfantAngiogenesis InhibitorsBevacizumabBiomarkers, TumorNeuropilin-1Neuropilin-2neuropilin-2, humanReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-3VEGFA protein, humanantiangiogenic therapybevacizumabgliomaVEGFVEGF receptors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.